Terrific insights as always from Adam Hill CEO of Oncimmune
Well worth watching
www.voxmarkets.co.uk/articles/q-a-with-oncimmune-ceo-dr-adam-m-hill-5f97846 |
KT_AIM
you must have been reading the wrong NICE report cos the one that is available speaks highly of EarlyCDT |
Does deflecting attention away from core business work?
Their Early CDT Lung tech doesn't work; recent NICE report pretty damning.
Perhaps it's a hidden gem, i'm just not seeing it |
Interim results within the next week will hopefully give the market a better understanding of where this business is at. |
Today’s fall appears to be collateral damage from SNGs fall today. We saw similar when POLX had their FDA application thrown back. Punters who overexposed themselves on SNG are having to sell other shares to cover their position. A poster elsewhere has confirmed he was a reluctant seller today. |
3 comments in 2 months, I love it. Just confirms what a hidden gem that this is.
I am certain that the market does not understand the ImmunoINSIGHTS business and the commercial and medical importance of discovering and validating novel biomarkers, improving disease stratification and understanding disease heterogeneity.
Management are not yet explaining this business, its uniqueness and wider strategic importance in a way that allows a majority of investors to grasp the full extent of the opportunity in front of it. I don't think it would be a bad idea to do it in crayons, I almost mean this literally. A couple of slides in a IR preso that are overly simplified and visual would do wonders in my opinion. |
More encouraging contract news today from immunodiagnostics firm Oncimmune
Find out what this means here.
www.linkedin.com/posts/paul-hill-a5994116_onc-onc-onc-activity-6899259635661164544-T6I- |
Bear or bull? |
Adam buying again |
FY22 is set to be a transformational year for next generation, immunodiagnostics firm Oncimmune
Find out why here.
www.linkedin.com/posts/paul-hill-a5994116_onc-immunoinsights-keytruda-activity-6878975378770190337-tdox |
Another cracking update!! |
Come on Adam get some contracts out |
Brummy git=Paul Hill ;-) |
Thanks coalfired.
Yes, Oncimmune (starts 28:00) was mentioned positively here on yesterday's Vox "stock picking' video.
www.linkedin.com/posts/paul-hill-a5994116_stocks-to-follow-on-vox-markets-101221-activity-6875044390188982272-YiKA |
Mentioned on vox markets today. Takeover valuation of £4 talked about |
Looks like the seller has cleared this morning. And More big news coming before Xmas (see todays RNS!) |
Buy, hold and then sell for multiples. Simple really |
Excellent trading update today from Oncimmune.
All the news & commentary here.
www.linkedin.com/posts/paul-hill-a5994116_onc-immunoinsights-activity-6873894018355392512-fDFB |
www.voxmarkets.co.uk/articles/stocks-to-follow-on-vox-markets-be10a70
ONC 40:15 |
Crazy price drop for minor sells and no tangible reason. |
Fantastic & importantly very insightful comments from CEO Adam M Hill, wrt the Oncimmune's exciting runway ahead.
www.voxmarkets.co.uk/articles/oncimmune-discuss-their-highly-profitable-immunoinsights-business-b95d977 |
Yeah that late payment has taken the shine of the forecasted revenues, but strong growth elsewhere and very positive noises for continued growth for 2022 |
Not (imo) encouraging finance-wise
"The revenue reported is lower than the headline £5.6M indicated in the unaudited full-year trading update issued on 8 June, due largely to revenue recognition relating to an invoice for £1.7M to an historic EarlyCDT Lung distributor. The Group is unable to recognise this revenue in the year ended 31 May 2021 as the revenue recognition requirements of IFRS 15 have not been met at this time"
However encouraging progress with technology adopters - |
GLA for tomorrow! |
More marvellous contract news from Oncimmune - a pioneering immunodiagnostics firm.
All the commentary here.
www.linkedin.com/posts/paul-hill-a5994116_onc-immunoinsights-activity-6845604965579325440-_YDA |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
